Objective: To observe the clinical effect of Sangjiao Decoction on treatment of type 2diabetes.Methods: 103 cases of type 2 diabetes patients were divided into two groups at random.In test group,52 cases were given conventional western medical hypoglycemic treatment,alimentary control combined with Sangjiao Decoction.In control group,51 cases were given conventional western medical hypoglycemic treatment and alimentary control.The courses of treatment were both 30 days.Results: Sangjiao Decoction can improve clinical symptoms of type 2 diabetes markedly,the total effective rate of test group and control group was 63.46% and 19.61% respectively.Conclusion: Songjiao Decoction has good synergistic results in reduction of blood glucose and treatment of type 2 diabetes.

Objective To observe the effect of Wuyaojing granules(WYJG) on immunological function of mice.Methods Mice were randomly divided into six groups:the high-dosage WYJG group(6.0g/kg),the midst-dosage WYJG group (2.0g/kg),the low-dosage WYJG group(1.0g/kg),the Lindera aggregate group (0.9g/kg),the korean Ginseng group (2.0g/kg) and the normal control group(H2O).After a period of 30-day treatment,the effects of WYJG on the T lymphocyte transformations capacity induced by ConA,delayed hypersensitivity leaded by DNFB,the number of lymphocyte B,serum level of hemolysin and NK activity were observed. Results The high-dosage and the low-dosage WYJG could significantly increase T lymphocyte transformations capacity induced by ConA(P0.05).Conclusion WYJG can significantly increase T lymphocyte transformations capacity induced by ConA and strengthen delay hypersensitivity leaded by DNFB.

To investigate the effect of berberine on glycemia regulation in rats with diabetes and the related mechanisms.Diabetic-like rat model was successfully induced by intraperitoneal injection of streptozotocin in 50 out of 60 male SD rats, which were then randomly divided into 5 groups with 10 rats in each:control group (received vehicle only), positive drug control group (sitagliptin 10 mg·kg·d), low-dose berberine group (30 mg·kg·d), moderate-dose berberine group (60 mg·kg·d), and high-dose berberine group (120 mg·kg·d). All animals were fed for 3 d, and fasting blood sampling was performed on day 3 of administration. Rats were given glucose (2 g/kg) by gavage 30 min after the last dose. Blood and intestinal samples were obtained 2 h after glucose loading. Fasting blood glucose (FBG) and 2-h postprandial plasma glucose (2h-PPG) were detected by using biochemical analyzer, and insulin, glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-Ⅳ(DPP-Ⅳ) were measured by using ELISA kit.No significant difference in FBG and serum DPP-Ⅳ level were found between berberine groups and control group (all>0.05). Compared with control group, serum levels of GLP-1 and insulin were increased in high-and moderate-dose berberine groups, while 2h-PPG was decreased (all<0.05); GLP-1 levels in the intestinal samples were increased, while DPP-Ⅳ levels were decreased in all berberine groups (all<0.05).Short-term berberine administration can decrease 2h-PPG level in streptozotocin-induced diabetic rat model through local inhibition of intestinal DPP-Ⅳ. The efficacy of DPP-Ⅳ inhibitor may be associated with its intestinal pharmacokinetics.
Animals ; Berberine ; pharmacokinetics ; pharmacology ; Blood Glucose ; drug effects ; Diabetes Mellitus, Experimental ; chemically induced ; drug therapy ; Dipeptidyl Peptidase 4 ; analysis ; drug effects ; pharmacokinetics ; Dipeptidyl-Peptidase IV Inhibitors ; Dose-Response Relationship, Drug ; Glucagon-Like Peptide 1 ; analysis ; blood ; Hypoglycemic Agents ; Insulin ; blood ; Intestines ; chemistry ; drug effects ; Male ; Rats ; Rats, Sprague-Dawley ; Sitagliptin Phosphate